Hydra Biosciences Enters into Collaboration Agreement with Boehringer Ingelheim
Hydra Biosciences enters into an agreement with Boehringer Ingelheim to research and develop small-molecule TRP inhibitors for renal diseases and disorders.
Hydra Biosciences announced on Apr. 13, 2015 that it entered into a research collaboration and license agreement with Boehringer Ingelheim to identify small-molecule transient receptor potential (TRP) inhibitors focused on the treatment of renal diseases and disorders. As part of the agreement, Boehringer Ingelheim will take responsibility for global development and commercialization of the TRP inhibitors that come from the collaboration. The financial details of the agreement were not disclosed, however, Hydra will receive an upfront payment, additional funding for research, and will be eligible to receive milestone payments and tiered royalty payments depending on product sales.
“This partnership between Boehringer Ingelheim and Hydra Biosciences provides an excellent opportunity to maximize the potential of novel targets that may offer meaningful improvements in the treatment of chronic kidney diseases and other related diseases and disorders. Boehringer Ingelheim’s long track record of research, development and commercialization success makes them the perfect partner for this program,” said Russell Herndon, president and CEO of Hydra Biosciences, in a press release.
Source: Hydra Biosciences
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
